Daré Bioscience (DARE) Jones Healthcare and Technology Innovation Conference 2025 summary

Strategic vision and approach

• Focused on transforming women's health by addressing unmet needs with evidence-based treatments and rapid commercialization.

• Utilizes a dual-path approach to accelerate access, leveraging both FDA approval and 503(b) outsourcing facility pathways.

• Strategic collaborations and partnerships expand impact and capabilities across six targeted product areas.

• Emphasizes fiscal responsibility and broad access through multiple healthcare channels.

• Leverages known active pharmaceutical ingredients to speed development and market entry.

Product pipeline highlights

• Sildenafil cream for female sexual arousal disorder targets Q4 availability via 503(b) prescription, with parallel FDA approval pursuit.

• Ovaprene, a once-a-month non-hormonal contraceptive, is in phase 3 with a commercialization agreement with Bayer.

• Dare HPV, an antiviral vaginal capsule for HPV, is supported by a $10 million ARPA-H grant and aims to start phase 2 next year.

• Hormone therapy and non-hormonal options for menopause, including a monthly vaginal ring and vaginal tamoxifen, are in development.

• XACIATO, a treatment for bacterial vaginosis, achieved FDA approval and is commercially available in the US.

Market opportunity and innovation

• Women's health R&D has been underfunded, yet products represent 27% of blockbuster drugs.

• Large unmet needs exist in contraception, menopause, and sexual health, with millions of potential users.

• Innovation includes repurposing established APIs and developing first-in-category products.

• Dual-path and consumer health strategies enable faster access and revenue generation.

• Grant and non-dilutive funding support early-stage pipeline development.